21617-19-6Relevant articles and documents
Method for preparing 1-(4-chlorphenyl)-pyrazolidine-3-one
-
Paragraph 0064; 0065-0067; 0079-0081; 0091-0094, (2021/02/10)
The invention relates to the field of bactericide synthesis, and discloses a method for preparing 1-(4-chlorphenyl)-pyrazolidine-3-one. The method comprises the following steps: 1) reacting parachloroaniline with acrylic acid to obtain an addition reactio
Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
-
Page/Page column 78; 79, (2008/06/13)
The invention provides compounds of formula I: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.
Pyridocarbazole derivatives having cGMP-PDE inhibitory activity
-
, (2008/06/13)
PCT No. PCT/JP97/01829 Sec. 371 Date Jan. 29, 1998 Sec. 102(e) Date Jan. 29, 1998 PCT Filed May 29, 1997 PCT Pub. No. WO97/45427 PCT Pub. Date Dec. 4, 1997The invention relates to novel pyridocarbazole derivatives having highly selective action in inhibiting cyclic GMP-phosphodiesterase (hereinafter abbreviated as cGMP-PDE), processes for producing such derivatives, agents containing at least one of such derivatives as an active ingredient for preventing and/or treating pulmonary hypertension, ischemic heart diseases or diseases against which the cGMP-PDE inhibitory action is effective, and intermediates useful for the production of pyridocarbazole derivatives.